Scholarlink

<p>Effective predictive biomarkers for immunotherapy in breast cancer remain elusive, limiting precision treatment strategies. Although the biological significance of HER2‑low expression has gained increasing attention, its impact on immunotherapy response remains unknown. Here, we investigated the impact of HER2 expression on response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and explored the underlying biological patterns through comprehensive multi-omics analysis. A multi-center real-world cohort study revealed that HER2-low TNBC patients had poorer responses to immunotherapy than HER2-0 patients, whereas no significant difference was observed in chemotherapy alone; these findings were validated in independent prospective cohorts (ISPY-2 and NeoTRIP). Single‑cell multi‑omics further demonstrated that HER2‑low tumors exhibited reduced expression of major histocompatibility complex and immune checkpoint molecules, along with diminished T‑cell activity, relative to HER2‑0 tumors. Following immunotherapy, HER2‑low tumors showed no significant downregulation of targeted immune checkpoint molecules and less pronounced T‑cell clonal remodeling. Collectively, these findings establish HER2‑low expression as a negative predictor of immunotherapy response, shaped by a less immunogenic tumor microenvironment. These results provide important insights into the distinct immunological features of HER2‑low triple‑negative breast cancer and warrant further mechanistic and clinical investigations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Hewei Ge,
  • Yuhan Wei,
  • Yalong Qi,
  • Hongnan Mo,
  • Jingtong Zhai,
  • Cheng Zeng,
  • Xiaoying Sun,
  • Fei Ma

摘要

Effective predictive biomarkers for immunotherapy in breast cancer remain elusive, limiting precision treatment strategies. Although the biological significance of HER2‑low expression has gained increasing attention, its impact on immunotherapy response remains unknown. Here, we investigated the impact of HER2 expression on response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and explored the underlying biological patterns through comprehensive multi-omics analysis. A multi-center real-world cohort study revealed that HER2-low TNBC patients had poorer responses to immunotherapy than HER2-0 patients, whereas no significant difference was observed in chemotherapy alone; these findings were validated in independent prospective cohorts (ISPY-2 and NeoTRIP). Single‑cell multi‑omics further demonstrated that HER2‑low tumors exhibited reduced expression of major histocompatibility complex and immune checkpoint molecules, along with diminished T‑cell activity, relative to HER2‑0 tumors. Following immunotherapy, HER2‑low tumors showed no significant downregulation of targeted immune checkpoint molecules and less pronounced T‑cell clonal remodeling. Collectively, these findings establish HER2‑low expression as a negative predictor of immunotherapy response, shaped by a less immunogenic tumor microenvironment. These results provide important insights into the distinct immunological features of HER2‑low triple‑negative breast cancer and warrant further mechanistic and clinical investigations.